Skip to main content

Alembic Pharmaceuticals receives USFDA Approval for Midodrine Hydrochloride Tablets USP

Apollo Pharmacy hiring

Pharma courses

Apollo Pharmacy hiring

pharma courses

USFDA Approval for Midodrine Hydrochloride Tablets USP

Alembic Pharmaceuticals Limited announced it has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), ProAmatine Tablets, 2.5 mg, 5 mg, and 10 mg, of Takeda Pharmaceuticals USA, Inc. (Takeda). Midodrine Hydrochloride Tablets are indicated for the treatment of symptomatic orthostatic hypotension (OH).

Midodrine Hydrochloride Tablets USP 2.5 mg, 5 mg, and 10 mg have an estimated market size of US$ 60 million for twelve months ending September 2020 according to IQVIA.

Alembic has a cumulative total of 138 ANDA approvals (120 final approvals and 18 tentative approvals) from USFDA.

<< Back to Pharma News


Subscribe to PharmaTutor News Alerts by Email